Mitsubishi UFJ Asset Management UK Ltd. bought a new stake in shares of Illumina, Inc. (NASDAQ:ILMN) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 16,200 shares of the life sciences company’s stock, valued at approximately $2,811,000. Illumina makes up about 2.5% of Mitsubishi UFJ Asset Management UK Ltd.’s holdings, making the stock its 14th largest position.
A number of other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Advocacy Wealth Management Services LLC bought a new position in Illumina during the first quarter worth $102,000. Gemmer Asset Management LLC increased its stake in shares of Illumina by 5.7% in the first quarter. Gemmer Asset Management LLC now owns 686 shares of the life sciences company’s stock valued at $117,000 after buying an additional 37 shares in the last quarter. Advisory Services Network LLC acquired a new stake in shares of Illumina during the first quarter valued at about $117,000. Patten Group Inc. increased its stake in shares of Illumina by 2.7% in the first quarter. Patten Group Inc. now owns 965 shares of the life sciences company’s stock valued at $166,000 after buying an additional 25 shares in the last quarter. Finally, NN Investment Partners Holdings N.V. increased its stake in shares of Illumina by 11.3% in the second quarter. NN Investment Partners Holdings N.V. now owns 985 shares of the life sciences company’s stock valued at $171,000 after buying an additional 100 shares in the last quarter. 93.91% of the stock is owned by institutional investors and hedge funds.
Shares of Illumina, Inc. (ILMN) traded down 0.98% during trading on Friday, reaching $189.32. The company’s stock had a trading volume of 882,072 shares. The firm’s 50-day moving average is $181.43 and its 200 day moving average is $174.88. The company has a market cap of $27.64 billion, a PE ratio of 37.99 and a beta of 0.83. Illumina, Inc. has a 52-week low of $119.37 and a 52-week high of $199.95.
Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Tuesday, August 1st. The life sciences company reported $0.82 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.68 by $0.14. The business had revenue of $662 million during the quarter, compared to the consensus estimate of $642.38 million. Illumina had a return on equity of 19.69% and a net margin of 30.27%. The company’s quarterly revenue was up 10.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.86 EPS. On average, equities research analysts predict that Illumina, Inc. will post $3.65 EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This piece was reported by BNB Daily and is owned by of BNB Daily. If you are reading this piece on another publication, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be viewed at https://www.baseball-news-blog.com/2017/08/19/mitsubishi-ufj-asset-management-uk-ltd-acquires-new-stake-in-illumina-inc-nasdaqilmn-updated-updated-updated.html.
Several brokerages recently issued reports on ILMN. Barclays PLC reissued an “equal weight” rating and issued a $150.00 price objective on shares of Illumina in a research note on Wednesday, August 9th. Vetr raised Illumina from a “hold” rating to a “buy” rating and set a $209.78 price objective for the company in a research note on Wednesday, August 9th. BidaskClub raised Illumina from a “sell” rating to a “hold” rating in a research note on Monday, August 7th. Cowen and Company reaffirmed an “outperform” rating and set a $200.00 price target on shares of Illumina in a research note on Wednesday, August 2nd. Finally, Zacks Investment Research downgraded Illumina from a “buy” rating to a “hold” rating in a research note on Friday, August 4th. Three research analysts have rated the stock with a sell rating, nine have given a hold rating and eleven have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $177.01.
In other news, Director Jay T. Flatley sold 20,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 15th. The stock was sold at an average price of $194.73, for a total value of $3,894,600.00. Following the transaction, the director now owns 539,176 shares in the company, valued at approximately $104,993,742.48. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Omead Ostadan sold 1,671 shares of Illumina stock in a transaction that occurred on Monday, August 7th. The stock was sold at an average price of $195.26, for a total transaction of $326,279.46. Following the completion of the sale, the executive vice president now directly owns 24,571 shares in the company, valued at approximately $4,797,733.46. The disclosure for this sale can be found here. Insiders have sold a total of 154,010 shares of company stock valued at $27,840,615 in the last quarter. Company insiders own 1.60% of the company’s stock.
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.